Transparency Council: optometrist advice, epilepsy and allergic rhinitis

Agenda:

1. Preparation of a position on the qualification of the health care service "Optometrist's advice" as a guaranteed benefit.
2. Drug/reimbursement technology assessments:

Legrex (ticagrelorum) + ASA - prevention of cardiovascular events in adults after myocardial infarction and at high risk of cardiovascular events.

Legrex (ticagrelorum) + ASA - prevention of cardiovascular events in adults with acute coronary syndrome (ACS).

Itulazax (betula verrucosa) - treatment of allergic rhinitis and/or conjunctivitis caused by birch allergen homologs in children and adolescents 5-17 years old (diagnosis: history + positive allergy test to birch homolog family: spot skin tests and/or sIgE).

CRYSVITA (burosumabum) - evaluation under drug program B.151 "Treatment of patients with X-linked hypophosphatemia".

Columvi (clofitamabum) - evaluation under drug program B.12.FM "Treatment of patients with B-cell lymphoma (ICD-10: C82, C83, C85)".

Ospolot (sultiamum) - legitimacy of reimbursement approvals for indications:
- epilepsy, drug-resistant epilepsy,
- drug-resistant epilepsy in the course of Rett syndrome.

Inovelon (rufinamidum) - legitimacy of reimbursement approvals for indications:
- drug-resistant epilepsy,
- Lennox-Gastaut syndrome.

Fycompa (perampanelum) - legitimacy of reimbursement approvals for indications:
- drug-resistant epilepsy,
- drug-resistant epilepsy with focal seizures.

Source: AOTMiT